Your browser doesn't support javascript.
loading
Metformin-induced weight loss in patients with or without type 2 diabetes/prediabetes: A retrospective cohort study.
Chukir, Tariq; Mandel, Lindsay; Tchang, Beverly G; Al-Mulla, Nada A; Igel, Leon I; Kumar, Rekha B; Waitman, Jonathan; Aronne, Louis J; Shukla, Alpana P.
Afiliação
  • Chukir T; Department of Medicine, Division of Endocrinology, Diabetes, and Metabolism, Weill Cornell Medicine and NewYork-Presbyterian Hospital, 525 E 68thSt. F20, New York, NY, 10065, USA.
  • Mandel L; Weill Cornell Medicine, 1300 York Ave, New York, NY, 10065, USA.
  • Tchang BG; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA.
  • Al-Mulla NA; Weill Cornell Medicine-Qatar, Education City, Al Luqta St, Ar-Rayyan, Doha, P.O. Box 24144, Qatar.
  • Igel LI; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA.
  • Kumar RB; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA.
  • Waitman J; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA.
  • Aronne LJ; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA.
  • Shukla AP; Department of Medicine, Division of Endocrinology, Diabetes & Metabolism, Comprehensive Weight Control Center, Weill Cornell Medicine, 1165 York Ave, New York, NY, 10065, USA. Electronic address: aps2004@med.cornell.edu.
Obes Res Clin Pract ; 15(1): 64-68, 2021.
Article em En | MEDLINE | ID: mdl-33386253
It is unknown whether weight loss outcomes differ with metformin monotherapy in patients with obesity with or without type 2 diabetes (T2DM)/prediabetes (PreDM). In this retrospective study, 6- or 12-month weight loss outcomes were compared in 222 patients with or without T2DM/preDM who completed metformin monotherapy. Average weight loss was similar between groups, euglycemic vs. T2DM/preDM (6 months: 6.5 [6.0%] vs. 6.5 [6.1%] p = 0.97; 12 months: 7.4 [6.2%] vs. 7.3 [7.7%], p = 0.92). Categorical weight losses (≥5% and ≥10% of baseline weight) were also similar. Comparable clinically significant weight loss was achieved with metformin monotherapy in patients with obesity with or without T2DM/PreDM.
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Redução de Peso / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina Tipo de estudo: Etiology_studies / Observational_studies Limite: Humans Idioma: En Revista: Obes Res Clin Pract Ano de publicação: 2021 Tipo de documento: Article
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Estado Pré-Diabético / Redução de Peso / Diabetes Mellitus Tipo 2 / Hipoglicemiantes / Metformina Tipo de estudo: Etiology_studies / Observational_studies Limite: Humans Idioma: En Revista: Obes Res Clin Pract Ano de publicação: 2021 Tipo de documento: Article